Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: A retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group

Yoshikiyo Ito, Toshihiro Miyamoto, Tomohiko Kamimura, Ken Takase, Hideho Henzan, Yasuo Sugio, Koji Kato, Yuju Ohno, Tetsuya Eto, Takanori Teshima, Koichi Akashi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is considered the only curative treatment for relapsed or refractory follicular lymphoma (FL), but it has a high treatment-related mortality rate. Only a few reports, however, have described the efficacy of allo-SCT for FL in the Japanese population. We retrospectively analyzed the outcome of allo-SCT in 30 patients with FL. Seventeen (56.7 %) patients were chemorefractory, whereas 13 (43.3 %) were chemosensitive. An estimated 2-year overall survival rate (OS) and relapse rate of all patients was 46.7 and 20.0 %, respectively. There were no significant differences in the estimated 2-year OS rate between patients who received myeloablative conditioning and those who received reduced-intensity conditioning (P = 0.98), and among the recipients of related bone marrow (BM)/peripheral blood stem cell, unrelated BM and umbilical cord blood (P = 0.20). In patients who were either chemosensitive or chemorefractory at allo-SCT, the 2-year OS rate was 69.2 and 29.4 % (P = 0.06). Patients with mild-to-moderate acute GVHD had better 2-year PFS rate compared with patients who had severe acute GVHD (P = 0.01), but not better PFS compared with patients who had no acute GVHD (P = 0.12). Our results suggest that the graft-versus-lymphoma effects of allo-SCT may provide survival benefits even in patients with chemorefractory FL.

Original languageEnglish
Pages (from-to)463-471
Number of pages9
JournalInternational journal of hematology
Volume98
Issue number4
DOIs
Publication statusPublished - Oct 1 2013

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this